News
Study describes the structural and functional effects of several mutations on the androgen receptor
The androgen receptor is the main target in the fight against prostate cancer. The study, published in the journal Science Advances, states that the analyzed mutations affect several functional regions of the union domain of the androgen receptor to testosterone.
The DACMA Association donates 10,000 euros for breast cancer research
Yesterday, this association from Sant Joan Despí organized an event in which Dr. Sonia Pernas from IDIBELL and the ICO presented the current situation of breast cancer research.
Smoking increases the risk of developing severe COVID by 30 to 50%
This is the main conclusion of a study published in the scientific journal ‘European Respiratory Review’ in which the head of the IDIBELL Tobacco Control research group and head of the Tobacco Control Unit of the Catalan Institute of Oncology, Esteve Fernández, has participated. The article analyzes the results in this field in the different reports presented to date.
The Association Against Cancer in Barcelona finances four IDIBELL projects with almost 500,000 euros
The IDIBELL projects by Elisa Espinet, Juan José Rojas, Carolina M. Florian, and Victor Moreno have been selected. All of them presented this Monday in an act with a round table of the most outstanding grants and a dialogue between doctor and patient.
New study identifies an epigenetic signature associated to the rare genetic disorder GATA2 deficiency
The results show that patients with this disorder have abnormal genetic and epigenetic patterns, which could contribute to the development of diverse clinical manifestations, such as compromise the ability of blood cell production.
IDIBELL and CNIO researchers propose biomarkers to select patients with breast cancer who could benefit from treatment with Denosumab
“These results reactivate the option of clinical trials with Denosumab in breast cancer selected patients”, says Eva González-Suarez, CNIO and IDIBELL researcher and lead author.
Brachytherapy in early-stage breast cancer tumors is faster and with fewer side effects than conventional radiotherapy
These are the results of an international study with the participation of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL) and the Valencian Institute of Oncology (IVO) and in which they make a comparison between the two techniques.
Bellvitge Hospital, IDIBELL and Astrazeneca test an application that monitors heart failure using voice
Through a mobile device, HearO™ makes it possible to predict possible complications in patients with heart failure through speech, detect disease-related fluid accumulation and alert the doctor before hospitalization
Research team from IDIBELL and UB find that HERC1 protein deficiency causes osteopenia
Scientists from IDIBELL and the University of Barcelona identify how HERC1 deficiency unbalances bone homeostasis, causing osteopenia. These results identify potential therapeutic targets for individuals with bone diseases and HERC1 deficiency.